Pharmavite launches four new supplements
NORTHRIDGE, Calif. — Pharmavite launched four new products onto retail shelves in March, including two gummy vitamins, an immune-system booster and an omega-3 supplement.
"We strive to develop products that meet consumers' needs, and the breadth of our new product line up this year is no exception to this commitment," stated Tim Toll, chief customer officer at Pharmavite. "As a leading brand in the vitamin and supplement industry, we take pride in developing quality products that help consumers meet their daily nutritional needs."
The new products include:
- Nature Made Omega-3 with Xtra Absorb Technology. This supplement is designed to provide superior absorption of heart healthy omega-3 fatty acids through the company's patented technology. The product's Xtra Absorb Technology creates micro-droplets that enhance the absorption of EPA and DHA omega-3s to provide almost four times better absorption that standard fish oil concentrate;
- Nature Made Immune Care Daily Support. Immune Care charges the body's natural immune defenses through the power of green tea;
- Nature Made Dual Action Digestive Probiotic + Energy B12 Gummies. The gummies, which come in raspberry and cherry flavors, are formulated with probiotics and vitamin B12 to support cellular energy production; and
- Nature Made Adult Gummies for Him Plus Omega-3s. Formulated with the male cosumer in mind, these gummies combine 11 key nutrients of daily nutritional support.
Osato International brings papaya-based immunity booster to U.S.
LOS ANGELES — Osato International recently brought Immun’Âge, a fermented papaya preparation, to the U.S. market. According to Osato, the superfood supplement helps boost the immune system and serves as an antioxidant.
"Many of the chronic ailments afflicting us as we age have multiple origins and a common factor – oxidative stress," noted Pierre Mantello, executive director of the Osato Research Institute. "Immun’Âge is easily ingested and has proven to have remarkable antioxidant and immunostimulating properties."
The process behind Immun’Âge begins on Hawaii's Big Island, where the only non-GMO-certified papayas are grown at the Diamond Head Papay Co., the company reported. The fermentation process takes 10 months.
According to the company, Immun’Âge is a popular food supplement in Italy, with additional distribution across Europe.
Greater number of allergy sufferers turn to OTC solutions, CHPA, Nielsen study finds
WASHINGTON — New research from the Consumer Healthcare Products Association and Nielsen released Thursday indicated that more Americans are suffering from seasonal allergies and are choosing nonprescription treatments over prescription medications.
“Less than 20 years ago nearly all allergy treatment options were prescription, but now the script is flipped and most of the options are OTC,” stated Scott Melville, president and CEO of CHPA. “Access and affordability has increased significantly now that more allergy medicines have switched from prescription to OTC.”
“Chronic diseases like allergies can be a burden on health, finances and time,” added Andrew Mandzy, director of the Health & Wellness Growth & Strategy team at Nielsen. “Now people have more options than ever for self-care, like leveraging online sources to find health-related information or by using OTC medicines as a first line of defense.”
According to the research, approximately 28% of Americans in 2015 reported that they suffer from seasonal allergies, with the majority of allergy sufferers (60%) saying they choose OTC medicines alone as their preferred treatment method. This represents a 20% increase from 2009.
The study also showed 75% of allergy sufferers purchased an OTC medication either on its own or in addition to a prescription treatment in 2015, compared to just 66% in 2009, suggesting that consumers have adjusted their behavior as more OTC options have become available over the past several years.
Although a custom survey in the report also showed that fewer allergy sufferers are going to healthcare providers for treatment, survey respondents did say that HCPs remain an important resource in managing their allergies. In 2015, 28% of allergy sufferers went to see an HCP for treatment (compared to 31% in 2009), and 44% of them stated that the HCP influenced their choice of OTC allergy medicines.
“It’s gratifying to know that patients still look at healthcare providers as an important part of their allergy management,” commented Cary Sennett, president and CEO of the Asthma and Allergy Foundation of America. “Even though most allergy medicines are conveniently available over-the-counter today, doctors still play a vital role in allergy diagnosis and management, especially for those who have a more severe form of the disease and for those who also have allergic asthma.”
These findings are part of a multi-year study on patient behavior, preferences, treatment dynamics, and costs, which are published in the new report, “Assessing Consumer Benefits of Allergy Rx-to-OTC Switches.”